Abstract: Over the past decade, numerous targeted therapeutic agents have become available for clinical use in the oncologic setting with the hopes of realizing personalized cancer treatment. These agents have achieved great improvements in clinical outcomes for patients suffering from solid and hematologic malignancies. However, adverse cutaneous reactions are among the most common toxicities observed in patients undergoing treatment with a targeted agent and can alter the overall clinical management strategy. For these reasons, the practicing dermatopathologist should be mindful of the breadth and depth of adverse cutaneous reaction patterns associated with this mechanistically diverse array of targeted agents.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2kbJzjT
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Caring for Patients with Physical Disabilities: Assessment of an Innovative Spinal Cord Injury Session that Addresses an Educational Gap Des...
-
Objective Outpatient parenteral antimicrobial therapy (OPAT) provides opportunities for improved cost savings, but in the UK, implementation...
-
Geriatric trauma: A population-based study Saint Shiou-Sheng Chen, Li-Chien Chien Formosan Journal of Surgery 2019 52(2):39-44 Background: G...
-
Ocular Vestibular Evoked Myogenic Potentials: Where Are We Now? Objective: Over the last decade, ocular vestibular evoked myogenic potential...
-
Abstract Objective To study the effects of Astragalus polysaccharide (APS), the primary effective component of the Chinese herb medicine A...
-
Abstract Objective To evaluate Chinese medicine (CM) formula Bazheng Powder (八正散) as an alternative therapeutic option for female patients...
-
Related Articles Disrupted relationship between "resting state" connectivity and task-evoked activity during social percepti...
-
World Community; and Remarks on our Own Behalf Models of Anticipation Within the Responsible Research and Innovation Framework: the Two RRI ...
-
Abstract Eslicarbazepine acetate is a new anti-epileptic drug belonging to the dibenzazepine carboxamide family that is currently approved ...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου